February 10, 2017
Amgen co-founder, Amarantus director Dr Joseph Rubinfeld, dies
Amgen co-founder Dr. Joseph Rubinfeld, who was an independet director of Amarantus BioScience Holdings has died.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 10, 2017
Canadian Crescita seeks new CFO
Canadian commercial dermatology company Crescita Therapeutics has named its Corporate Controller Ms. Muneerah Kanji as Interim Chief Financial Officer.
February 10, 2017
Aytu sales up by 47% from September for first ever $1M-plus sales quarter. Reduces net loss
Aytu BioScience, a drugmaker focused on urology products, has increased gross product sales by 47% from the quarter ended September 30, 2016 to the quarter ended December 31, 2016, from $925,000 to $1,358,000, getting its first ever $1M-plus quarter sales.
February 10, 2017
Hybrigenics gives update on chronic myeloid leukemia study
Hybrigenics has given an update on the Phase II clinical study of inecalcitol in chronic myeloid leukemia (CML) administered in addition to imatinib, the reference inhibitor of BCR-ABL kinase used as standard of care for CML.
February 10, 2017
Muscular Dystrophy Association welcomes FDA’s grant for Marathon’s Emflanza
The Muscular Dystrophy Association said yesterday it welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (Emflaza), developed by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.
February 10, 2017
Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial
NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.
February 9, 2017
Pharmaceuticals Analytical Testing Outsourcing Market Worth $9.6 Billion By 2025
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand.
February 9, 2017
Forward Pharma cashes in Biogen’s $1.25 billion
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
February 9, 2017
FDA approves Marathon Pharmaceuticals’s orphan drug
The U.S. Food and Drug Administration (FDA) has approved Marathon Pharmaceuticals’s Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.
February 9, 2017
Regeneron full year, quarter income up, global Praluent full year sales jump from $11M to $116M
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.